Endocyte’s target price
Endocyte (ECYT) is a clinical-stage biopharmaceutical company focused on advancing its two next-generation oncology platforms, radioligand therapies in metastatic castration-resistant prostate cancer indications and the adaptor-controlled autologous CAR-T program in osteosarcoma indications.
The company has reported a return of 309.58% in 2018 on a YTD (year-to-date) basis.
Wall Street analysts have projected Endocyte’s 12-month consensus target price to be $23.33, 33.09% higher than the company’s last closing price on September 21. The company’s last closing price of $17.53 is 1,188.97% higher than its 52-week low of $1.36 and 15.92% lower than its 52-week high of $20.85.
The 12-month consensus analyst recommendation for Endocyte as of September 23 is a “strong buy.”
The above diagram highlights Endocyte’s research programs across investigational therapies and indications in greater detail.
Of the four analysts covering Endocyte in September, three have rated the company as a “strong buy,” and one has rated the company as a “buy.”
On June 30, Endocyte had cash and cash equivalents worth $166.79 million on its balance sheet, significantly higher on both a YoY (year-over-year) and a sequential basis. The company expects to have more than $130 million in cash on its balance sheet by the end of 2018. The company expects to manage to fund its Phase 3 VISION trial, which is currently enrolling patients, as well as a proof-of-concept study for CAR-T therapy.
Analysts expect Endocyte to report revenues of $0.09 million, $0.05 million, and $22.40 million in 2018, 2019, and 2020, respectively. Analysts have also projected cash and cash equivalents on the company’s balance sheet to be $100.38 million, $244.74 million, and $87.42 million at the end of 2018, 2019, and 2020, respectively.
In the next article, we’ll discuss growth prospects for TG Therapeutics in greater detail.